MedPath
FDA Approval

MITIGO

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
December 27, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Morphine(500 mg in 20 mL)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Piramal Critical Care, Inc.

805600439

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Patheon Manufacturing Services LLC

Piramal Critical Care, Inc.

Piramal Critical Care, Inc.

079415560

Products2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

MITIGO

Product Details

NDC Product Code
66794-162
Application Number
ANDA204393
Marketing Category
ANDA (C73584)
Route of Administration
EPIDURAL, INTRATHECAL
Effective Date
December 27, 2023
WATERInactive
Code: 059QF0KO0RClass: IACT
SULFURIC ACIDInactive
Code: O40UQP6WCFClass: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
MorphineActive
Code: X3P646A2J0Class: ACTIBQuantity: 500 mg in 20 mL

MITIGO

Product Details

NDC Product Code
66794-160
Application Number
ANDA204393
Marketing Category
ANDA (C73584)
Route of Administration
EPIDURAL, INTRATHECAL
Effective Date
December 27, 2023
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT
MorphineActive
Code: X3P646A2J0Class: ACTIBQuantity: 200 mg in 20 mL
SULFURIC ACIDInactive
Code: O40UQP6WCFClass: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
WATERInactive
Code: 059QF0KO0RClass: IACT
© Copyright 2025. All Rights Reserved by MedPath